#Lcsm

Nathan A. Pennell MD, PhD, FASCO

I messed up my poster so attaching slides here (Abstract 9529: A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with

1/Fantastic talk by @CharuAggarwalMD on molecular/biomarker testing & data. Why is it important? Targeted therapy improves outcomes, IO does not work for everyone & IO b4 TKIs has been associated

Can we achieve similar outcomes for lung #SABR in non-academic institutions compared to the major academic centres? This was an important question posed by @drdavidpalma Suresh Senan & @FJLagerwaard. This

#ESMO20 Much anticipated results from CodeBreaK100: AMG 510 (sotorasib) in #KRAS G12C #NSCLC by @DavidHongMD building on exciting data seen over the past two years for this huge unmet need.

Nathan A. Pennell MD, PhD, FASCO

THREAD: I have heard a lot of self-righteous indignation about how we would be bankrupting the system with adjuvant targeted treatment for EGFR mutation+ NSCLC pts, so let's take a

Uppity Cancer Pt

If you end up at the ER, don't say that you have terminal cancer. This will close doors. Thank you @drdonsdizon #bcsm #lcsm #bccww #covid19ncancer https://twitter.com/drdonsdizon/status/1248948968136093699 Who else wants to

A few years before the RTOG 0236 reported a local tumor control rate of 91% with lung SBRT (2010), the Z4033 trial explored RFA as an alternative. The key findings

Myvizhi Esai Selvan

Excited to share that our work “Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk” is now published in JTO: 1/7 @JTOonline@SinaiGenetics @IcahnInstitute #lcsm https://pubmed.ncbi.nlm.nih.gov/32866655/ O

KartikSehgal_MD

Delay/extension of pembro-based Rx for advanced NSCLC expected #COVID19. In preprint @medRxiv, our experience with outcomes in patients who received atleast ≥4 cycles and had delays/extensions. Results hypothesis-generating only but

Today at #AACR21 I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who

Santiago Viteri

I am honored to be part of this piece of the lung cancer story. Tepotinib in NSCLC with MET exon 14 skipping mutations. #NSCLC #METex14 #Tepotinib #LCSM https://www.nejm.org/doi/full/10.1056/NEJMoa2004407?source=nejmtwitter&medium=organ

How might we design a palliative care model for people with brain tumors AND their care partners?1st: Define quality of life (QoL)This study used Twitter to better understand how people

Mike Thompson, MD, PhD, FASCO

1/ [THREAD] Timeline @ASCO Social Media & Analyses [Updated: May 22, 2020] #socialoncology #socpharm #ASCO20 #ASCO20 Tweeps -- remember to Report (& Block) SPAMmers using oncology hashtags. Clean